Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inviragen Inc.

Division of Takeda Pharmaceutical Co. Ltd.
www.inviragen.com

Latest From Inviragen Inc.

Takeda-Zydus Enter Increasingly Crowded Chikungunya Fray

Takeda and Zydus Cadila are stepping into the fray to develop a vaccine for chikungunya, an increasingly crowded segment that now has over a dozen candidates in various stages of development.

Research & Development Infectious Diseases

Takeda Gains On Sanofi As Two-Shot Dengue Vaccine Advances

While Sanofi late last year became the first company to commercialize a vaccine for dengue, Takeda has strengthened its position as the likely next to market contender following the start of a global Phase III program for its rival product.

Research & Development Infectious Diseases

Takeda Cements Norovirus Lead Through Vaccine Trial Start

Takeda has initiated dosing in the first field trial globally with a candidate vaccine for norovirus, maintaining its clear development lead in the area.

BioPharmaceutical United States

Sinovac’s Pioneering EV71 Vaccine Set To Reach First Market

The China FDA has given a production nod to Beijing Sinovac for its EV71 vaccine, which now appears set to be the first product of its type globally to be commercialized. The company expects to launch the vaccine in June and is also actively seeking partners in other Asian countries.

BioPharmaceutical China
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • InViragen LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Dan Stinchcomb, PhD, CEO
    Jorge Osorio, PhD, CSO
    Joseph Santangelo, PhD, COO
    Gilad Gordon, MD, CMO
  • Contact Info
  • Inviragen Inc.
    Phone: (970) 672-4918
    1613 Prospect Pkwy.
    Ste. 100
    Fort Collins, CO 80525
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register